SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
June 6, 2014
TG Therapeutics, Inc.
(Exact name of registrant as specified in
|(State or other jurisdiction of
|incorporation or organization)
3 Columbus Circle, 15th Floor
New York, New York 10019
(Address of principal
executive offices, including Zip Code)
(Registrant's telephone number, including
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|o||Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|o||Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|o||Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|o||Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|Item 5.07.||Submission of Matters
to a Vote of Security Holders.
TG Therapeutics, Inc. (the “Company”)
held its annual meeting of stockholders on Friday, June 6, 2014 at the offices of its legal counsel, Alston & Bird LLP, 90
Park Avenue, New York, New York 10016 at 10:30 a.m. Eastern Standard Time. Stockholders representing 31,304,385, or 83.20%, of
the 37,624,407 shares entitled to vote were present in person or by proxy. Proxies were solicited by the Company pursuant to Regulation
14A under the Securities Exchange Act of 1934, as amended. At the annual meeting, Proposals 1, 2 and 3 were approved. The proposals
below are described in detail in the Company’s definitive proxy statement dated April 23, 2014 for the annual meeting.
The results are as follows:
The following persons were nominated and elected directors:
Michael S. Weiss
|Laurence N. Charney
||William J. Kennedy
||Mark Schoenebaum, MD
The shareholder voting for board members is summarized as follows:
|Michael S. Weiss
|Laurence N. Charney
|William J. Kennedy
|Mark Schoenebaum, MD
All six directors will serve on the board of directors of the
Company until the 2015 annual meeting.
CohnReznick LLP was approved as the Company’s independent
registered public accountant for the fiscal year ending December 31, 2014.
The votes cast were as follows:
An amendment to the Company’s Certificate of Incorporation
to decrease its authorized share capital by 350,000,000 shares from 500,000,000 to 150,000,000 was approved.
cast were as follows:
At its board of directors meeting held on
June 6, 2014, the Company’s board of directors approved the following changes to the compensation paid to non-employee directors:
|•||Annual Retainer: Increased from $25,000 to $50,000; and
|•||Additional Retainer for
Audit Committee Chair: Increased from $5,000 to $10,000.
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 10, 2014
Sean A. Power
Title: Chief Financial Officer